--- a
+++ b/clusters/3009knumclusters/clust_292.txt
@@ -0,0 +1,620 @@
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1,200/ul
+Absolute neutrophil count (ANC) >= 1,500/uL, obtained within 4 weeks prior to randomization
+Absolute neutrophil count >= 1500/uL; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility
+Peripheral absolute neutrophil count (ANC) >= 750/uL
+Peripheral absolute neutrophil count (ANC) >= 1000/uL
+Peripheral absolute neutrophil count (ANC) >= 1000/uL for patients with solid tumors without bone marrow involvement
+Peripheral absolute neutrophil count (ANC) >= 750/uL for patients with solid tumors and known bone marrow metastatic disease
+Absolute neutrophil count (ANC) >= 750/uL (>= 0.75 X 10^9/L), within 14 days of registration
+Absolute neutrophil count (ANC) >= 1250/ul
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count >= 1,500/ul
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1,500/ul without the use of hematopoietic growth factors (within 14 days of treatment initiation)
+Peripheral absolute neutrophil count (ANC) >= 750/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count >= 1,500/ul
+Absolute neutrophil count > 1,500/uL
+Absolute neutrophil count ? 1,000/microliter (uL)
+Absolute neutrophil count (ANC) >= 1500/uL, within 14 days of registration
+Absolute neutrophil count > 1000 /uL
+Absolute neutrophil count (ANC) ? 1500/uL
+Absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+ANC < 1500/ul
+Absolute neutrophil count (ANC) >= 750/uL for subjects without bone marrow involvement
+Absolute neutrophil count (ANC) >= 750/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count >= 1,500/uL
+Peripheral absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count >= 1,000/ul
+Absolute neutrophil count >= 1.5 K/uL
+Absolute neutrophil count (ANC) ? 1000/uL
+Absolute neutrophil count ? 1,000/ul
+Absolute neutrophil count 1500/ul or more
+Obtained =< 21 days prior to registration: absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count >= 1.5 K/uL
+Absolute neutrophil count (ANC) >= 1500/uL performed within 30 days prior to the date of registration
+Absolute neutrophil count (ANC) >= 1,500 cells/uL
+Obtained within 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count >= 1.5 K/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Documented within 14 days of registration: Absolute neutrophil count >= 1000/ul (unsupported)
+Absolute neutrophil count >= 1.5 K/uL
+Obtained =< 21 days prior to registration and confirmed prior to the first dose of study drug: Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) ? 1,500/uL within 28 days prior to registration
+Absolute neutrophil count >= 1.5 K/uL within 14 days prior to start of protocol therapy.
+Absolute neutrophil count ? 1.5 K/uL
+Absolute neutrophil count (ANC) >= 1500/uL (with/without growth factor)
+Absolute neutrophil count (ANC) ? 750/uL\r\n* The above criteria do not have to be met if the patient has bone marrow involvement of tumor
+Absolute neutrophil count (ANC) > 1500 cells/uL
+Within 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,500/uL
+PHASE I: Absolute neutrophil count >= 1500/uL
+PHASE IB: Absolute neutrophil count >= 1500/uL
+OBTAINED =< 7 DAYS PRIOR TO REGISTRATION: Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count >= 1000 cells/uL
+INCLUSION CRITERIA FOR STRATUM C: Absolute neutrophil count >= 1000 cells/uL
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count < 1,000/uL
+Absolute neutrophil count (ANC) >= 1,500 cells/ul
+INCLUSION - TREATMENT: Absolute neutrophil count (ANC) >500/ul
+Peripheral absolute neutrophil count (ANC) >= 750/uL
+Absolute neutrophil count (ANC) >= 1,500 cells/ul
+Absolute neutrophil count >= 1500/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute granulocyte count >= 1000 K/uL
+Absolute neutrophil count =< 1,500/uL
+Absolute neutrophil count >= 1.0 K/uL
+Absolute neutrophil count (ANC) >= 1500/uL.
+Absolute neutrophil count (ANC) >= 1000 cells/uL
+Absolute neutrophil count >= 1,500/uL
+Neutropenia (absolute neutrophil count [ANC] < 1000 cells/ul)
+Absolute neutrophil count (ANC) >= 1,500/uL within 14 days prior to first dose of protocol-indicated treatment.
+Absolute neutrophil count (ANC) >= 1500 cells/uL.
+Absolute neutrophil count (ANC) < 1,500/uL
+Absolute neutrophil count (ANC) > 1,000/uL
+Within 10 days prior to the start of study treatment: Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) ? 1000/uL, with or without chronic granulocyte growth factor support
+Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1500 uL
+Absolute neutrophil count (ANC) >= 1,000/uL
+Within 28 days prior to treatment start: Absolute neutrophil count (ANC) >= 1500/ul
+Absolute neutrophil count (ANC) > 1,000/uL.
+Absolute neutrophil count ? 500/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count >= 500 /uL
+Absolute neutrophil count (ANC) >= 1.5 k/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+STUDY TREATMENT: Absolute neutrophil count (ANC) >= 1500 cells/uL within 14 days prior to the first study treatment.
+Absolute neutrophil count ? 1,500/uL
+Absolute neutrophil count (ANC) >= 1,500/ uL, within 2 weeks of registration
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count >= 750 cells/uL
+Absolute neutrophil count >= 1,500/ul
+Peripheral absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count >= 1,000/uL (unsupported), within 14 days of registration and within 7 days of the start of treatment
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count >= 1,500 cells/uL
+Absolute neutrophil count > 1,500/uL
+Absolute neutrophil count 1500/ul or more
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 /uL)
+Absolute neutrophil count < 1000/uL at the screening visit
+Absolute neutrophil count (ANC) > 1000/ul
+Absolute neutrophil count (ANC) >= 1500 ul
+Absolute neutrophil count 1500/ul or more
+Absolute neutrophil count (ANC) >= 1500 ul.
+Absolute neutrophil count (ANC) > 1000/uL
+Absolute neutrophil count >= 1,500/uL.
+Absolute neutrophil count (ANC) >= 1,000 cells/uL
+Obtained within 14 days of the first study treatment: Absolute neutrophil count (ANC) > 1500 cells/ul
+Absolute neutrophil count >= 1.5 K/UL
+Absolute neutrophil count > 1.5 K/uL
+Absolute neutrophil count >= 1500/uL
+Absolute neutrophil count (ANC) > 1 K/uL.
+Absolute neutrophil count >= 1,500/uL
+ANC (Absolute neutrophil count) >= 1000/ul (unsupported)
+Absolute neutrophil count (ANC) 1.0 x 10^9/L (1,000/uL)
+Absolute neutrophil count (ANC) >= 1,500 cells/ul (prior to biopsy)
+Absolute neutrophil count >= 1,500/uL.
+Absolute neutrophil count (ANC) > 1,000/uL unless disease-related (due to marrow infiltration or splenomegaly)
+Absolute neutrophil count (ANC) >= 1,500/uL
+Within 28 days prior to enrollment: Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) of >= 1,000/uL
+Obtained within 14 days of the first study treatment: Absolute neutrophil count (ANC) > 1500 cells/ul
+Absolute neutrophil count >= 750/uL
+Absolute neutrophil count >= 1500/uL
+Absolute neutrophil count (ANC) >= 1500 cells/uL
+No more than 14 days prior to registration: Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count >= 1,000/uL
+Performed within 14 days of treatment initiation: Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) < 500/uL
+Absolute neutrophil count (ANC) >= 1500/ul within 14 days of cycle 1 day 1
+absolute neutrophil count (ANC) >= 1500/ul
+Absolute neutrophil count (ANC) > 1,000/uL
+Absolute neutrophil count (ANC) >= 1,500/ul
+Absolute neutrophil count >= 1,500 uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1500/uL obtained =< 14 days prior to registration
+Absolute neutrophil count > 750 cells/uL
+Absolute neutrophil count (ANC) >= 1,500/ uL, within 2 weeks of registration (except where specified otherwise)
+Absolute neutrophil count >= 1,200/uL
+Absolute neutrophil count >= 1,500 /uL
+Absolute neutrophil count [ANC] >= 1500 cells/uL
+Absolute neutrophil count (ANC) =< 1,000/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Patients must have an absolute neutrophil count (ANC) greater than or equal to 1500/uL
+Absolute neutrophil count (ANC) >= 1500/ul
+Neutrophil count >= 1000/uL prior to biopsy
+Neutrophil count >= 1500 uL
+Within 14 days prior to the first study treatment (cycle 1, day 1): Absolute neutrophil count (ANC) >= 1500 cells/uL
+Absolute neutrophil count (ANC) >= 1500 cells/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1000/uL, within 14 days of study registration (within 30 days for pulmonary and cardiac assessments)
+ANC ? 1000/uL
+Peripheral absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) < 1500 cells/uL
+Absolute neutrophil count ?1000/uL
+Absolute neutrophil count (ANC) >= 1500 cells/uL (obtained within 28 days prior to first study treatment)
+Within 14 days of registration: Absolute neutrophil count (ANC) >= 1500/ul
+Absolute neutrophil count >= 1,500/uL
+FOR MULTIPLE MYELOMA ONLY: Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1500/uL; filgrastim can be given before and during treatment to achieve target ANC >= 1500 uL
+Absolute neutrophil count >= 1,500/uL within 14 days prior to study entry
+Absolute neutrophil count (ANC) ? 1500 cells/uL within 14 days prior to the first study treatment (cycle 1, day 1)
+Absolute neutrophil count (ANC) >= 1,500/uL (performed within 28 days of registration)
+Absolute neutrophil count (ANC) > 1000/uL should be obtained within 21 days prior to enrollment
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1000/uL at screening visit
+Absolute neutrophil count >= 1200/uL performed within 7 days of treatment initiation
+Absolute neutrophil count (ANC) > 1000/uL
+Absolute neutrophil count (ANC) >= 1500 cells/uL
+Absolute neutrophil count (ANC) >= 1000/uL obtained =< 14 days prior to registration
+Absolute neutrophil count > 1,500/uL
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1500 cells/uL
+Absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) or atypical glandular cell (AGC) >= 1500 per uL
+Absolute neutrophil count > 1,500 uL
+Absolute neutrophil count >= 1,500/uL
+Peripheral absolute neutrophil count (ANC) >= 1,000/uL
+Recovery from induction therapy (absolute neutrophil count [ANC] > 200/ul, platelet count > 20,000/ul)
+Absolute neutrophil count (ANC) < 200/ul prior to treatment
+Absolute neutrophil count (ANC) > 1000/uL
+Patients must have absolute neutrophil count (ANC) >= 1000/uL; neupogen can be given before and during treatment to achieve target ANC >= 1000/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1500/ul
+Absolute neutrophil count >= to 1,500 /uL
+Absolute neutrophil count >= 1,000/uL within 30 days prior to course 1 day 1 (C1D1)
+Absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count (ANC) should be > 500/uL
+Absolute neutrophil count (ANC) > 1000/uL
+Absolute neutrophil count (ANC) >= 1500/uL, without cerebrospinal fluid (CSF) support
+Absolute neutrophil count (ANC) >= 1,500 cells/ul without growth factor support
+Absolute neutrophil count >= 1,200/ul
+Absolute neutrophil count >= 1,500/uL obtained within 14 days of first treatment
+Absolute neutrophil count (ANC) >= 1,000 cells/ul
+Absolute neutrophil count (ANC) >= 1500 cells/uL
+Absolute neutrophil count (ANC) >= 1500 cells/uL
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count >= 1,000/uL
+Within 3 months of registration: Absolute neutrophil count (ANC) >= 1000 cells/uL
+Absolute neutrophil count < 1500/uL
+Absolute CD4 count > 200 cells/uL
+Within 14 days prior to study entry: Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count >= 500/ul
+Absolute neutrophil count (ANC) >= 1,500/uL
+ARM A COHORT 1: Absolute neutrophil count >= 1,500/ul
+ARM B COHORT 2: Absolute neutrophil count >= 1,500/ul
+ARM B COHORT 3: Absolute neutrophil count >= 1,500/ul
+ARM C COHORT 4: Absolute neutrophil count >= 1,500/ul
+Absolute neutrophil count (ANC) >= 1,500/ul
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1500 cells/ul
+Absolute neutrophil count (ANC) > 1,000/ul
+Must be met within 28 days of C1D1: Absolute neutrophil count (ANC) >= 1,500/ul
+Absolute neutrophil count >= 1,500/uL
+INCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count > 1,000/ul
+Absolute neutrophil count (ANC) of >= 1000/uL
+Absolute neutrophil count (ANC) >= 1000/uL, obtained =< 14 days prior to registration
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1,500/uL, performed within 28 days prior to registration
+Absolute neutrophil count >= 1,500/uL within 14 days of the first dose of study drug
+Absolute neutrophil count >= 1,500/uL obtained no more than 28 days prior to the start of neoadjuvant endocrine therapy
+Absolute neutrophil count (ANC) >= 1,500 cells/ul
+Absolute neutrophil count (ANC) < 1500/uL
+Absolute neutrophil count >= 1.5 k/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Peripheral absolute neutrophil count (ANC) ? 750/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count >= 1,500 cells/uL (to be performed within 7 days prior to start of study treatment)
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) greater than 500/uL
+Absolute neutrophil count >= 1500/uL
+Absolute neutrophil count (ANC) >= 1500/uL (obtained =< 7 days prior to registration)
+Absolute neutrophil count (ANC) >= 1.5 x 10 (3)uL
+Absolute neutrophil count >= 1,500/ul
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1,500 cells/ul
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1000 cells/uL
+Absolute neutrophil count >= 1,500/ul
+Absolute neutrophil count (ANC) >= 1000/ul
+Absolute neutrophil count (ANC) >= 1,000 cells/uL
+Absolute neutrophil count (ANC) > 1,000/ul
+Absolute neutrophil count >= 1,000/uL (within 2 weeks prior to radiotherapy)
+Absolute neutrophil count >= 500/ul (phase I only)
+Absolute neutrophil count >= 1500/uL
+Absolute neutrophil count (ANC) > 1500/uL
+Absolute neutrophil count (ANC) >= 1500 uL
+Absolute neutrophil count (ANC) > 1,000/uL
+Neutrophil count >= 1000 /uL
+Absolute neutrophil count (ANC) >= 1,500 /uL
+Absolute neutrophil counts >= 1,500 cells per uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Peripheral absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count >= 500/ul
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count (ANC) =< 1000/ul
+Absolute neutrophil count (ANC) > 1,000/ul
+Absolute neutrophil count >= 1,500/ul
+Treatment indicated based on demonstration of at least one of the following no more than 4 weeks from the time of enrollment, and no less than 6 months after prior cladribine and no less than 4 weeks after other prior treatment, if applicable:\r\n* Neutropenia (absolute neutrophil count [ANC] < 1000 cells/ul)\r\n* Anemia (hemoglobin [Hgb] < 10g/dL)\r\n* Thrombocytopenia (platelets [Plt] < 100,000/ul)\r\n* Absolute lymphocyte count (ALC) of > 5,000 cells/uL\r\n* Symptomatic splenomegaly\r\n* Enlarging lymph nodes > 2 cm\r\n* Repeated infections requiring oral or i.v. antibiotics
+Absolute neutrophil count (ANC) >= 1,000/ul
+Absolute neutrophil count (ANC) >= 1,500/ul within 7 days prior to starting treatment
+Absolute granulocyte count < 1,500/ul
+Absolute granulocyte count < 1,500/ul
+Absolute neutrophil count (ANC) > 1,500/uL
+Patients must have an absolute neutrophil count (ANC) > 1000/ul and a platelet count > 50,000/ul
+Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1000/uL (without growth factor support)
+Absolute neutrophil count (ANC) >= 1500/ul
+Absolute neutrophil count > 1,500/uL during screening evaluation
+Absolute neutrophil count (ANC) >= 1500/ul
+Peripheral absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1,500 cells/ul
+Absolute neutrophil count >= 1,500/uL
+Within 14 days prior to the first study treatment (cycle 1, day 1): Absolute neutrophil count (ANC) >= 1500 cells/uL.
+Absolute neutrophil count (ANC) >/= 1,500 cells/ul without growth factor support prior to initial treatment
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Obtained =< 7 days prior to registration: Absolute neutrophil count >= 1500/uL
+Absolute neutrophil count >= 1500 cells/uL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)
+Absolute neutrophil count >= 1,500/ul
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Peripheral absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count 1500/ul or more
+Neutrophil count >= 1,500/ul
+Absolute neutrophil count (ANC) >= 1,000/ul
+Absolute neutrophil count (ANC) > 1,500/uL
+Patients must have absolute neutrophil count (ANC) > 1000/uL
+Secondary Registration: absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) => 1500/uL
+Absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1500/uL, specimens must be collected within 10 days prior to the start of study treatment
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count >= 1,500/uL
+Peripheral absolute neutrophil count (ANC) > 1,000/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Peripheral absolute neutrophil count (ANC) >= 750/uL\r\n* If the ANC and/or platelet count are not adequate, but due to bone marrow metastatic disease, these criteria will be waived
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1500 cells/uL
+For patients with solid tumors without bone marrow involvement: peripheral absolute neutrophil count (ANC) >= 1000/uL
+For patients with solid tumors and known bone marrow metastatic disease: peripheral absolute neutrophil count (ANC) >= 750/uL
+Absolute neutrophil count: >= 1,500/ul
+Within 14 days of subject registration: Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) > 1,500/uL
+Absolute neutrophil count (ANC) >= 1,500/ul
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) > 1500/uL
+Absolute neutrophil count >= 1,500/uL
+Peripheral absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1,000 cells/uL
+Absolute neutrophil count (ANC) >= 1,500/ul
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) < 750/uL, if these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy)
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1000/ul
+Peripheral absolute neutrophil count (ANC) >= 1000/uL (must not have received filgrastim [G-CSF] within the prior 7 days)
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) > 1,000/ul
+Absolute neutrophil count (ANC) > 1,500/ul
+Neutropenia (absolute neutrophil count [ANC] < 1000 cells/ul)
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1500/ul (without growth factor support)
+Performed within 14 days of patient registration: Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count >= 1500/ul
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count >= 1,500/ul
+Absolute Lymphocytes ?800/uL
+Absolute neutrophil count/absolute granulocyte count ?1500/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) ? 0.75 x 10^3/uL without treatment with a myeloid growth factor within 3 days prior to first dose of IP
+Absolute neutrophil count >= 1000/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1,500/ul
+Absolute neutrophil count (ANC) >= 1500/ul
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) ? 1000/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) >=1500/microlitre (uL).
+Absolute neutrophil > 1000/uL
+Absolute neutrophil count >= 1,000/ul
+Absolute neutrophil count: >=1,000/uL
+Absolute neutrophil count (ANC) >= 1,000/uL unless due to bone marrow involvement
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) > 1,500/uL
+Peripheral absolute neutrophil count (ANC) >= 750/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) > 750/uL
+Absolute neutrophil count (ANC) should be > 500/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count >= 1500 /uL
+Absolute neutrophil count (ANC) >= 1500/ul
+Absolute neutrophil count (ANC) >= 1000/uL, obtained =< 21 days prior to registration and confirmed prior to the first dose of study drug
+Within 14 days prior to registration: absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count >= 1,500/uL obtained =< 7 days prior to randomization
+Absolute neutrophil count (ANC) > 1000 K/uL independent of transfusion support
+Absolute neutrophil count >= 1.0 K/uL
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Within 14 days prior to the first study treatment (cycle 1, day 1): Absolute neutrophil count (ANC) >= 1500 cells/uL
+Absolute neutrophil count (ANC) > 1500/uL
+Within 4 weeks of administration of study therapy: Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) > 1000 uL
+Absolute neutrophil count (ANC) >= 750 /uL obtained =< 7 days prior to registration
+Absolute neutrophil count (ANC) > 1500/ul
+Absolute neutrophil count (ANC) < 1,000/ul
+Absolute neutrophil count (ANC) >= 1,500 cells/ul
+Absolute neutrophil count (ANC) >= 1500 cells/uL
+Obtained =< 21 days prior to registration: Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1000/ul
+Absolute neutrophil count (ANC) >= 1,500 cells/uL
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 750 cells/uL within 14 days before enrollment
+Absolute neutrophil count >= 1,000/ul
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1000/uL
+Peripheral absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) > 1000/uL
+AT THE TIME OF INFUSION: Absolute neutrophil count (ANC) > 750/ul
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1,500/ul
+Absolute neutrophil count < 1,000/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count >= 1,500/uL
+Adequate bone marrow function (Absolute neutrophil count (ANC) ? 1,500 cells/uL; Platelets (PLT) ? 100,000 cells/uL)
+COHORT A: Absolute neutrophil count (ANC) >= 1000/uL
+COHORT B: ANC >= 1000/uL
+The peripheral absolute neutrophil count must be at least 1,500/uL
+Absolute neutrophil count (ANC) >= 1000/ul (unsupported)
+Absolute neutrophil count (ANC) greater than or equal to 1500/uL
+Absolute neutrophil count (ANC) >= 1500 / uL
+Absolute neutrophil count > 1,500/uL
+Obtained within 14 days prior to the first study treatment (cycle 1, day 1); absolute neutrophil count (ANC) ? 1500 cells/uL
+Absolute neutrophil count (ANC) >= 1000/ul
+Absolute neutrophil count (ANC) >= 1.0 K/uL, unless if cytopenias are deemed to be due disease at discretion of clinical investigator; transfusions and growth factors are permissible
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1,200/ul
+Neutropenia (absolute neutrophil count < 1 x 10^3/uL)
+Absolute neutrophil count (ANC) >= 750 cells/uL (0.75 x 10^9/L)
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1500/ul (without growth factor support)
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count >= 1000/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count >= 500/ul
+Absolute neutrophil count >= 1.5 K/UL
+Absolute neutrophil count (ANC) or absolute granulocyte count (AGC) >= 1500 per uL
+Peripheral absolute neutrophil count (ANC) >= 1000/uL
+Peripheral absolute neutrophil count (ANC) >= 750/uL
+Absolute neutrophil count (ANC) of less than 250 cells/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) =< 1500/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) >= 750/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count < 1,500/uL
+Absolute neutrophil count (ANC) >= 1500/uL, without cerebrospinal fluid (CSF) support
+Absolute neutrophil count >= 500/ul
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count >= 1,500 cells per uL
+Absolute neutrophil count (ANC) >= 1500/ul
+Absolute neutrophil count (ANC) >= 1,500/ul (unless due to bone marrow infiltration by tumor in which case ANC >= 500/ml are allowed)
+Absolute neutrophil count (ANC) < 1,500 /uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Obtained within 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,500/ul
+Absolute neutrophil count (ANC) >= 1,500 cells/uL
+Absolute neutrophil count >= 1,500/uL
+Peripheral absolute neutrophil count (ANC) >= 1,000/uL
+Within 14 days after subjects signed the treatment consent: Absolute neutrophil count (ANC) >= 1,500/ul
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count >= 1000/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1,500/ul
+Absolute neutrophil count (ANC): >= 1000/uL (~ 1 x 10^9/L)
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Neutrophil count >= 1,000/uL
+Absolute neutrophil count >= 1,500/uL, within 14 days of registration
+Absolute neutrophil count >= 1.5/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count >= 1500/uL
+Patients must have an absolute neutrophil count (ANC) >= 500/uL
+Absolute neutrophil count (ANC) >= 1,500/ul
+Absolute neutrophil count >= 1000/uL
+Absolute neutrophil count (ANC) >= 1,000/ul
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count >= 1500/uL within 30 days prior to registration
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1500 cells/uL (obtained within 14 days prior to the first study treatment [course 1, day 1])
+Within 14 days prior to enrollment/randomization: Absolute neutrophil count (ANC) > 1.5 K/uL
+Absolute neutrophil count (ANC) >= 1.0 K/uL
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1,500 cells/ul
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count >= 1000 uL
+Absolute neutrophil count > 1,500/ul
+Absolute neutrophil count (ANC) >= 1000/uL obtained =< 14 days prior to registration
+Absolute neutrophil count (ANC) >= 1,500/ul (unless low ANC is due to multiple myeloma)
+Absolute neutrophil count (ANC) > 1500/ul
+Absolute neutrophil count (ANC) =< 1,500 cells/ul
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) > 1000/ul
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) > 1,000 cells/ul
+Absolute neutrophil count of > 1000/ul
+Absolute neutrophil count (ANC) >= 1500/uL
+Neutropenia (absolute neutrophil count < 1 x 10^3/uL)
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) > 1,500/uL
+Absolute neutrophil count (ANC): >= 1000/uL (~0.5 x 10^9/L)
+Absolute neutrophil count (ANC) must be >= 1500/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count >= 750 cells/uL
+Absolute neutrophil count 1,500/uL
+Absolute neutrophil count > 1,500/uL
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1500/ul
+Absolute neutrophil count (ANC) >= 1000/ul
+Absolute neutrophil count > 1000/uL
+Absolute neutrophil count > 1,500/uL
+Absolute neutrophil count >= 1.0 K/uL (growth factor support is permissible)
+ANC ? 1000/uL
+Absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count (ANC): >= 1,500/ul
+Absolute neutrophil count (ANC) > 1,000/ ul 3
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1,500/ uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Peripheral absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count >= 1,500/uL
+Peripheral absolute neutrophil count (ANC) >= 750/uL
+Absolute Neutrophil Count (ANC) >= 1500/uL
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count >= 1,500/ul
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count (ANC) >= 1,500/ul
+Absolute neutrophil count (ANC) >= 1,500/ul
+Peripheral absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count >= 1.0 x 10^3/uL obtained at baseline (day 1 of cycle 1, before study drug administration)
+Absolute neutrophil count >= 1,500 cells/uL
+Absolute neutrophil count (ANC) >= 1000/ul
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1000/uL, unless due to bone marrow involvement by lymphoma
+An absolute neutrophil count (ANC) > 1500/ul
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count >= 1000uL
+Absolute neutrophil count >= 1000/uL
+Absolute neutrophil count > 1000/uL
+Absolute neutrophil count (ANC) > 1000/uL not supported by transfusions
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count >= 1500/ul
+Absolute neutrophil count (ANC) > 1.5 K/uL
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1200/uL
+Absolute neutrophil count (ANC) > 1,500 cells/ul within 14 days prior to treatment initiation
+Patients must have absolute neutrophil count (ANC) >= 1000/uL; Neupogen can be given prior to start of SGN-35 (brentuximab vedotin) and during SGN-35 treatment to achieve target ANC >= 1000/uL
+ANC >= 1000/uL
+Absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) > 1500/uL
+Absolute neutrophil count >= 1,500/ul
+Peripheral absolute neutrophil count (ANC) > 1,000/ul
+Abnormal marrow function as defined as absolute neutrophil count <1,500/ul or platelets <100,000/ul.
+Absolute neutrophil count > 1,500/uL
+Absolut neutrophil count (ANC) > 1500/uL
+Absolute neutrophil count >= 500/ul
+Absolute neutrophil count (ANC) >= 1,000/uL
+Absolute neutrophil count (ANC) > l500/ul
+Absolute neutrophil count (ANC) > 1500/uL
+Absolute neutrophil count (ANC) >= 1000/uL
+Absolute neutrophil count > 1,500/uL
+Absolute neutrophil count (ANC) >=1500/uL
+Absolute neutrophil count < 1500/uL
+Absolute neutrophil count > 1,500/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count (ANC) >= 1500 cells/uL (obtained within 28 days prior to the first study treatment)
+Patients with absolute neutrophil count (ANC) >= 1,000/uL; the most recent ANC level taken within 60 days prior to study enrollment will be considered
+Have documented lab work with absolute neutrophil count (ANC) >= 1.0 K/uL and platelets >= 50 K/uL in the past 12 months
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count (ANC) > 1,000 cells/ul
+Peripheral absolute neutrophil (ANC) >= 1000/uL
+ANC > 1000/uL
+Absolute neutrophil count (ANC) > 1500/ul
+Absolute neutrophil count >= 1500/uL
+Absolute neutrophil count (ANC) >= 500/ul without growth factor or transfusional support
+Absolute neutrophil count (ANC) >= 1500/uL
+Absolute neutrophil count >= 1500/uL
+Absolute neutrophil count (ANC) < 1,500 K/UL in the past 30 days
+Absolute neutrophil count (ANC) >= 1000/ul without growth factor or transfusional support
+Absolute neutrophil count (ANC) greater than 500/uL
+Absolute neutrophil count (ANC) < 1,500 K/UL in the past 30 days
+Neutropenia (serum absolute neutrophil count [ANC] < 1,000/uL)
+Absolute neutrophil count >= 1,000/uL
+Absolute neutrophil count >= 1,500/uL
+Neutrophil count >= 1,200/mm^3 (>= 1.2 k/uL)
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1,500/uL, obtained within 14 days prior to treatment start
+Within 30 days of eligibility confirmation: Absolute neutrophil count (ANC) >= 1,500 uL
+Absolute neutrophil count (ANC) ? 1000/uL
+Obtained within 28 days prior to registration: Absolute neutrophil count (ANC) >= 1500 cells/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count (ANC) >= 1500 cells/uL
+Absolute neutrophil count (ANC) >= 1500 cells/uL
+Peripheral absolute neutrophil count (ANC) >= 1000/uL (must not have received G-CSF [filgrastim] within the prior 7 days)
+Absolute neutrophil count (ANC) > 1500 cells/uL
+Absolute neutrophil count > 1,000/uL
+Absolute neutrophil count (ANC) >= 1,500/uL
+Absolute neutrophil count > 1,500/uL
+Absolute neutrophil count (ANC) >= 1000 cells/uL
+Absolute neutrophil count >= 1,500/uL
+Absolute neutrophil count > 1000/uL
+Absolute neutrophil count (ANC) > 1500/ul
+Absolute neutrophil count (ANC) ? 750/uL
+Absolute neutrophil count (ANC) ?1500/mm3 (?1.5 × 103/uL)